Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Mogamulizumab, sold under the brand name Poteligeo, is a humanized, afucosylated monoclonal antibody targeting CC chemokine receptor type 4 (CCR4). It is given by injection into a vein.
Read the full article on WikipediaCutaneous T-cell lymphoma Clinical criteria: Treatment Phase: Continuing treatment Patient must have previously received PBS-subsidised treatment with this drug for this condition, AND Patient must not have developed disease progression while receiving PBS-subsidised treatment with this drug for this condition, AND The treatment must be the sole PBS-subsidised therapy for this condition.
Working under the parallel aged-care framework? Aged-care equivalent →